3,>=4 prior line of therapy, GPRC5DxCD3 Bispecific Antibody, Subcutaneous Talquetamab 405 Μg Weekly
Subcutaneous Talquetamab 800 Μg Every 2 Weeks
Subcutaneous Talquetamab All Doses 
Intravenous Talquetamab All Doses, Relapsed Refractory Multiple Myeloma (RRMM), Phase 1
### Instruction:
Identify the study with the following condition. 
### Input:
3,>=4 prior line of therapy, GPRC5DxCD3 Bispecific Antibody, Subcutaneous Talquetamab 405 Μg Weekly
Subcutaneous Talquetamab 800 Μg Every 2 Weeks
Subcutaneous Talquetamab All Doses 
Intravenous Talquetamab All Doses, Relapsed Refractory Multiple Myeloma (RRMM), Phase 1 
### Output:
Popular Name is MonumenTAL-1, Study ID is NCT03399799